Triopsy Medical, Inc.
Triopsy Medical, Inc. manufacturer of Cancer Diagnosis system. Our new Triopsy approach will create opportunity across three key market segments: medical device, pathology systems, and mapping systems for more accurate diagnosis. Our novel biopsy and pathology technology will assess more accurately the precise tumor location, exact size, disease type and stage, genomic analysis, and pathway to personalized medicine.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Medical / Health Care
- Market Focus:
- Nationally (across the country)
About Us
Our new Triopsy™ approach will create opportunity across three key market segments: medical device, pathology systems, and mapping systems for more accurate diagnosis. Our novel biopsy and pathology technology will assess more accurately the precise tumor location, exact size, disease type and stage, genomic analysis, and pathway to personalized medicine.
We believe that our work will initially improve th...
We believe that our work will initially improve the lives of millions of men with prostate issues, and we will ultimately expand our work into many other areas where better accuracy, fewer errors, and lower costs can have a positive impact on health outcomes.
Ultimately, we are in the business of extending and saving lives. And we believe this work is accomplished by providing simple, thorough, and accurate processes and disciplines that support physicians in their work. One case, one biopsy, one sample – and one life at a time.
Our disruptive and innovative technology is addres...
Our disruptive and innovative technology is addressing a significant and unmet need - that is, to diagnose cancer more accurately and earlier. We are targeting a well-defined market opportunity with accessible channels of distribution and are pursuing a streamlined 510(k) regulatory pathway with go-to-market strategy planned for 2022.
Reimbursement codes already exist for our planned products with a related reimbursement strategy already in place, and there is value for all stakeholders – patients, physicians, hospitals, and payers.
The company was founded by internationally recognized experts in prostate cancer, and an experienced management team, scientific advisory board, and board of directors with a track record of success.